Dynavax Technologies
Blood & Organ Banks · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
2100 Powell St Ste 720, Emeryville, Cali...Phone Number
(510) 848-5100Website
www.dynavax.comRevenue
$330.5 MillionStock Symbol
DVAXIndustry
ZI Rank: 8
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
11
9
7
6
18
8
About Dynavax Technologies
Founded in 1996 and located in Emeryville, California, Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the bodys innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.Explore more
Dynavax Technologies Org Chart
SB
Senior Director, Financial Reporting & Techni...
JH
Product Finance Director, Corporate
EL
Global Director, Research Development & Opera...
NA
Communications Associate Director, Investor R...
DA
Global Associate Director, Payroll
ST
Associate Director, Revenue Accounting
BP
Associate Director, Accounting
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dynavax Technologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Dynavax Technologies
Click to see if Dynavax Technologies had a recent Job posting/layoffs
Product Launch: Get notified when Dynavax Technologies launches new products
Check out if Dynavax Technologies is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Dynavax Technologies recently announced quarterly report
Check if Dynavax Technologies has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Dynavax Technologies has new funding data
Dynavax Technologies, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Dynavax Technologies
Compare insights from companies similar to Dynavax Technologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$1.1B
501-1,000
Public
$3.2B
1987
RM
Raburn MallorySenior Vice President, Head of Clinical Development and Deputy Chief Medical Officer
$66.5M
201-500
Public
$260M
2016
DB
Deborah BartonSenior Chief Marketing Officer, EA Office of & Corporate Communications Business Partner
Company Profile Activity
Activity Insights
Dynavax Technologies is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Dynavax Technologies is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Dynavax Technologies.
Dynavax Technologies financials insights
Gather financial insights about Dynavax Technologies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2004
Stock Offering
$45M
2010
Stock Offering
$20.1M
Stock Offering
$43.9M
2013
Stock Offering
$85.9M
2021
Debt
$99M
Dynavax Technologies Tech Stack
A closer look at the technologies used by Dynavax Technologies
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Executive Moves, Acquisitions
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Compliance
Person-Based
Accounting, Compliance, Financial Reporting, Finance
Dynavax Technologies News & Media
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News
This vaccine-focused biotech reported a significant insider sale as it advances its hepatitis B franchise and global partnerships.Jim Cramer Highlights Sanofi’s Bid for Dynavax
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the stocks Jim Cramer recently looked at. When a caller noted that they bought the stock three years ago for around $12, Cramer remarked: “Congratulations. You know that one’s done. They got that nice bid from Sanofi. I’m going to actually go out there and talk to them […]$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX)
NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The...Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
NEW YORK and NEW ORLEANS, Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi (NYSE: SNY). Under...
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Dynavax Technologies
Sign Up For FreeTo access detailed company insights
Founded in 1996 and located in Emeryville, California, Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the bodys innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a va... Read More
